Pulmonary hypertension (PH) describes a hemodynamic condition with a pathological increase in pressure in the pulmonary vascular circulation. Clinically, PH causes reduced performance, shortness of breath, angina and syncope. Comprehensive diagnostics to exclude or classify the various underlying clinical pictures is essential, as the treatment of pulmonary hypertension sometimes differs considerably depending on the underlying disease.
Autoren
- Dr. med. Yaosi Li
- Dr. med. Daniel Grund
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Alopecia areata in children, adolescents, and adults
New Guideline Classifies the Evidence Base for Topical and Systemic Therapies
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases